Arabic Arabic English English French French German German
dark

Model-Integrated Evidence for Generic Drug Development – Session 1C

Presenters and a panel discuss exploring opportunities and challenges for utilizing artificial intelligence (e.g., machine learning and natural language processing) to support generic drug development and application assessment. Presentation titles include, “Artificial Intelligence in Pharmaceutics,” and “Artificial Intelligence in Generic Drug Development – Experience and Opportunities,” and “Improving Generic Drugs and Streamlining Their Approval Through Artificial Intelligence.”
Learn more at: https://www.fda.gov/drugs/news-events-human-drugs/fy-2021-generic-drug-science-and-research-initiatives-public-workshop-06232021-06232021
_______________________________ 
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.  

Upcoming Training – https://www.fda.gov/cdersbia   
SBIA Listserv – https://public.govdelivery.com/accounts/USFDA/subscriber/new?topic_id=USFDA_352
SBIA 2021 Playlist – https://youtube.com/playlist?list=PLey4Qe-UxcxYS1MaTusSgyifQDqdeepyD
SBIA LinkedIn – https://www.linkedin.com/showcase/cder-small-business-and-industry-assistance  
SBIA Training Resources – https://www.fda.gov/cderbsbialearn  
Twitter – https://twitter.com/FDA_Drug_Info  
Email – CDERSBIA@fda.hhs.gov  
Phone – (301) 796-6707 I (866) 405-5367

Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Model-Integrated Evidence for Generic Drug Development – Session 1B

Next Post

Complex Product Characterization/Analysis – Session 2A

Related Posts
Total
0
Share